Navigation Links
Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient

BEND, Oregon, December 15 /PRNewswire/ -- Bend Research Inc. announced today that its clients may now reference a key safety file for HPMCAS, an excipient used in technologies developed by the firm to enhance the oral bioavailability of clients' low-solubility drugs.

Bend Research clients may now reference a Type V Drug Master File (DMF) for HPMCAS for regulatory filings with the FDA, Bend Research officials said.

"We're excited about this new development and know it will assist our clients in accelerating the regulatory process for new therapeutic products," Bend Research CEO Rod Ray explained.

HPMCAS-hypromellose acetate succinate-is a polymeric excipient with a demonstrated safety record for use in humans. The polymer is used in Bend Research drug-delivery technologies such as spray-dried dispersions (SDDs), which have successfully enhanced the oral bioavailability for scores of low-solubility drugs.

The Type V DMF for HPMCAS was filed with the FDA in 2005 by Pfizer Inc., the sponsor of Bend Research's work investigating the use of HPMCAS to improve drug solubility. This Type V DMF contains supplemental nonclinical safety data-including absorption, distribution, metabolism, and excretion (ADME) data-to support chronic and high-dosage use of HPMCAS as an excipient for human oral delivery.

The Type V DMF supplements the DMF filed by Shin-Etsu Chemical Co. and provides additional data to support the use of HPMCAS in SDDs for improving oral drug bioavailability.

Bend Research clients may obtain a letter of authorization that allows the FDA to reference the Type V DMF for regulatory reviews such as Investigational New Drug (IND), New Drug Application (NDA), or Abbreviated New Drug Application (ANDA) reviews. (Contact: Dana Settell, 541-382-4100)

"The availability of the Type V DMF for HPMCAS adds significant value to the formulation work we perform for our clients," Ray said. "It provides additional safety data our clients can reference during the FDA approval process for the new therapeutics we develop with them."

About Bend Research Inc.

Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. The firm has a long, established track record of matching the right technologies with the customers' needs to provide a rapid, straightforward solution. As CEO Rod Ray states, "Our goal at Bend Research is to be the leading drug formulation problem-solving company in the world in terms of the best performance, speed, and cost-which all boils down to client value."

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.

The company's flexible, client-focused business model and collaborative approach to working with its customers result in long-term partnerships focused on value creation.

Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.


    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701
    Phone: +1-541-382-4100
    Fax: +1-541-382-2713

SOURCE Bend Research Inc.

SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
2. US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
3. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
4. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
5. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
6. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
7. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
8. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
9. New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults
10. Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker
11. Alzheimers Research May Lead to Preventing the Debilitating Disease
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
Breaking Medicine News(10 mins):